{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:11:18Z","timestamp":1780402278938,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jval.2023.10.014","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:21:37Z","timestamp":1699575697000},"page":"182-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non\u2013Small Cell Lung Cancer in ALTA-1L Trial"],"prefix":"10.1016","volume":"27","author":[{"given":"Jennifer L.","family":"Beaumont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamao M.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Geiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Hudgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jval.2023.10.014_bib3","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S1470-2045(16)30510-1","article-title":"Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards","volume":"17","author":"Bottomley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jval.2023.10.014_bib4","first-page":"573","article-title":"Patient outcomes, patient experiences and process indicators associated with the routine use of patient-reported outcome measures (PROMs) in cancer care: a systematic review","volume":"29","author":"Graupner","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jval.2023.10.014_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"5","key":"10.1016\/j.jval.2023.10.014_bib6","first-page":"264","article-title":"Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers","volume":"6","author":"Zagadailov","year":"2013","journal-title":"Am Health Drug Benefits"},{"issue":"4","key":"10.1016\/j.jval.2023.10.014_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jval.2020.11.004","article-title":"Past and current practice of patient-reported outcome measurement in randomized cancer clinical trials: a systematic review","volume":"24","author":"Giesinger","year":"2021","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2023.10.014_bib8","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jnci\/djz038","article-title":"Systematic evaluation of patient-reported outcome protocol content and reporting in cancer trials","volume":"111","author":"Kyte","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.jval.2023.10.014_bib9","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41591-022-01781-8","article-title":"Patient reported outcome assessment must be inclusive and equitable","volume":"28","author":"Calvert","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jval.2023.10.014_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s41687-020-00219-4","article-title":"The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders","volume":"4","author":"Cruz Rivera","year":"2020","journal-title":"J\u00a0Patient Rep Outcomes"},{"key":"10.1016\/j.jval.2023.10.014_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2019.08.016","article-title":"Current state of quality of life and patient-reported outcomes research","volume":"121","author":"Bottomley","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jval.2023.10.014_bib12","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.jval.2023.10.014_bib13","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"31","key":"10.1016\/j.jval.2023.10.014_bib14","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib versus crizotinib in advanced ALK inhibitor-I ALK-positive nonsmall cell lung cancer: second interim analysis of the Phase III ALTA-1L trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.jval.2023.10.014_bib15","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jval.2023.10.014_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lungcan.2021.03.005","article-title":"Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK+ nonsmall cell lung cancer (ALTA-1L)","volume":"155","author":"Garcia Campelo","year":"2021","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.jval.2023.10.014_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00439229","article-title":"The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual Life Res"},{"issue":"11","key":"10.1016\/j.jval.2023.10.014_bib18","first-page":"1753","article-title":"EORTC PROBE project and the Lung Cancer Group. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials","volume":"19","author":"Maringwa","year":"2011","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jval.2023.10.014_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2023.10.014_bib20","first-page":"179","article-title":"The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology: an update","volume":"2","author":"Aaronson","year":"1996","journal-title":"Qual Life Pharmacoecon Clin Trials"},{"issue":"5","key":"10.1016\/j.jval.2023.10.014_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials","volume":"30","author":"Bergman","year":"1994","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.jval.2023.10.014_bib22","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/10629360600810434","article-title":"Fully conditional specification in multivariate imputation","volume":"76","author":"Van Buuren","year":"2006","journal-title":"J\u00a0Stat Comput Simul"},{"key":"10.1016\/j.jval.2023.10.014_bib24","series-title":"Statistical Power Analysis for the Behaviors Science","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jval.2023.10.014_bib25","series-title":"Psychometric Theory","first-page":"248","article-title":"The assessment of reliability","author":"Nunnally","year":"1994"},{"issue":"5","key":"10.1016\/j.jval.2023.10.014_bib26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"issue":"5","key":"10.1016\/j.jval.2023.10.014_bib27","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s11136-022-03181-4","article-title":"How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales","volume":"32","author":"Cocks","year":"2023","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.jval.2023.10.014_bib28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jtho.2018.11.019","article-title":"Quality of life in NSCLC \u2013survivors - a multicenter cross-sectional study","volume":"14","author":"Hechtner","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jval.2023.10.014_bib29","first-page":"1023","article-title":"Quality of life of patients with lung cancer","volume":"9","author":"Polanski","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"suppl 2","key":"10.1016\/j.jval.2023.10.014_bib30","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.21037\/tlcr.2018.03.10","article-title":"Quality of life for nonsmall cell lung cancer patients in the age of immunotherapy","volume":"7","author":"Ramirez","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jval.2023.10.014_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/1471-2407-11-353","article-title":"Quality of life assessment as a predictor of survival in nonsmall cell lung cancer","volume":"11","author":"Braun","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jval.2023.10.014_bib32","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1186\/1471-2458-12-790","article-title":"Quality of life predicts survival in patients with nonsmall cell lung cancer","volume":"12","author":"Li","year":"2012","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.jval.2023.10.014_bib33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.athoracsur.2022.09.047","article-title":"Patient-reported physical function is associated with survival after lung resection for nonsmall cell lung cancer","volume":"116","author":"Pompili","year":"2023","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.jval.2023.10.014_bib34","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/icvts\/ivaa123","article-title":"Patients\u2019 views of routine quality of life assessment following a diagnosis of early-stage non-small cell lung cancer","volume":"31","author":"Pompili","year":"2020","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.jval.2023.10.014_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2022.10.003","article-title":"Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC","volume":"174","author":"Salomone","year":"2022","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.jval.2023.10.014_bib36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40271-022-00584-w","article-title":"Interpreting within-patient changes on the EORTC QLQ-C30 and EORTC QLQ-LC13","volume":"15","author":"Coon","year":"2022","journal-title":"Patient"},{"issue":"4","key":"10.1016\/j.jval.2023.10.014_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523061612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523061612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:37:06Z","timestamp":1761097026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301523061612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1098301523061612"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2023.10.014","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non\u2013Small Cell Lung Cancer in ALTA-1L Trial","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}